Becton Dickinson's most recent trend suggests a bearish bias. One trading opportunity on Becton Dickinson is a Bear Call Spread using a strike $130.00 short call and a strike $140.00 long call offers a potential 8.7% return on risk over the next 39 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $130.00 by expiration. The full premium credit of $0.80 would be kept by the premium seller. The risk of $9.20 would be incurred if the stock rose above the $140.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Becton Dickinson is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Becton Dickinson is bearish.
The RSI indicator is at 75.21 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Becton Dickinson
Becton, Dickinson Acquires GenCell Biosystems in Ireland
Tue, 14 Oct 2014 16:10:08 GMT
8:01 am Becton Dickinson acquires GenCell Biosystems
Mon, 13 Oct 2014 12:01:00 GMT
BD Acquires GenCell Biosystems
Mon, 13 Oct 2014 12:00:00 GMT
PR Newswire – FRANKLIN LAKES, N.J., Oct. 13, 2014 /PRNewswire/ — BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, announced today that it has acquired GenCell Biosystems, a privately-held Irish biotech company that has developed proprietary technologies that address key biological analysis protocols – from library preparation of Next Generation Sequencing (NGS) to genotyping for agricultural applications. “We are excited with the GenCell Biosystems acquisition as it provides BD entry into the Next Generation Sequencing market, a fast-growing segment with the potential to have a significant impact on healthcare,” said Linda Tharby, Group President, BD. “The acquisition gives BD access to the NGS market with a differentiated platform that will provide a base to further grow our genomics offerings.”
Sat, 11 Oct 2014 06:48:00 GMT
[$$] Last Week
Sat, 11 Oct 2014 06:27:00 GMT
Also on Market Tamer…
Follow Us on Facebook